Thomas E. Edwards

Thomas E. Edwards

Auto-generated profile, based on publicly available information

Thomas E. Edwards

Seattle Structural Genomics Center for Infectious Diseases, Seattle, Washington, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2015 in Science
Verified
Journal Article
Closed access
PDF file
TATodd C. Appleby
Todd C. Appleby
JPJason K. Perry
Jason K. Perry
EMEisuke Murakami
Eisuke Murakami
OBOna Barauskas
Ona Barauskas
JFJoy Feng
Joy Feng
TEThomas E. Edwards
Thomas E. Edwards
A view of the HCV polymerase at work: More than 3% of the world's population is infected with hepatitis C virus (HCV), a predisposing factor for life-threatening liver diseases such as cirrhosis and cancer. HCV encodes a polymerase called NS5B that catalyzes replication of the viral RNA genome. Drugs inhibiting NS5B have shown impressive antiviral activity in recent clinical trials. Appleby et al. (see the Perspective by Bressanelli) reveal the inner workings of HCV RNA replication by analyzing crystal structures of stalled NS5B polymerase ternary complexes during the initiation and elongation of RNA synthesis. They also define the way in which sofosbuvir, a drug with potent clinical efficacy, interacts with the NS5B active site. Science , this issue p. 771 ; see also p. 715

8 November 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DDDouglas R. Davies
Douglas R. Davies
AGAmy D. Gelinas
Amy D. Gelinas
CZChi Zhang
Chi Zhang
JRJohn C. Rohloff
John C. Rohloff
JCJeffrey D. Carter
Jeffrey D. Carter
TJThale C. Jarvis
Thale C. Jarvis
Selection of aptamers from nucleic acid libraries by in vitro evolution represents a powerful method of identifying high-affinity ligands for a broad range of molecular targets. Nevertheless, a sizeable fraction of proteins remain difficult targets due to inherently limited chemical diversity of nucleic acids. We have exploited synthetic nucleotide modifications that confer protein-like diversity on a nucleic acid scaffold, resulting in a new generation of binding reagents called SOMAmers (Slow Off-rate Modified Aptamers). Here we report a unique crystal structure of a SOMAmer bound to its target, platelet-derived growth factor B (PDGF-BB). The SOMAmer folds into a compact structure and exhibits a hydrophobic binding surface that mimics the interface between PDGF-BB and its receptor, contrasting sharply with mainly polar interactions seen in traditional protein-binding aptamers. The modified nucleotides circumvent the intrinsic diversity constraints of natural nucleic acids, thereby greatly expanding the structural vocabulary of nucleic acid ligands and considerably broadening the range of accessible protein targets.

1 September 2006 in Structure
Verified
Journal Article
Closed access
TEThomas E. Edwards
Thomas E. Edwards
AFAdrian R. Ferré-D'AMaré
Adrian R. Ferré-D'AMaré

22 February 2009 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
DKDaniel J Klein
Daniel J Klein
TEThomas E Edwards
Thomas E Edwards
AFAdrian R Ferré-D'Amaré
Adrian R Ferré-D'Amaré
Riboswitches are RNA domains that alter gene expression in response to ligand binding. The structure of the Bacillus subtilis preQ1 ribsoswitch, which recognizes the conserved modified nucleobase preQ1, in complex with its ligand indicates how an RNA of only 34 nucleotides recognizes its ligand. Riboswitches are mRNA domains that bind metabolites and modulate gene expression in cis. We report cocrystal structures of a remarkably compact riboswitch (34 nucleotides suffice for ligand recognition) from Bacillus subtilis that is selective for the essential nucleobase preQ1 (7-aminomethyl-7-deazaguanine). The structures reveal a previously unrecognized pseudoknot fold and suggest a conserved gene-regulatory mechanism whereby ligand binding promotes sequestration of an RNA segment that otherwise assembles into a transcriptional antiterminator.

1 June 2007 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
TEThomas E Edwards
Thomas E Edwards
DKDaniel J Klein
Daniel J Klein
AFAdrian R Ferré-D’aMaré
Adrian R Ferré-D’aMaré

1 October 2008 in Chemistry & Biology
Verified
Journal Article
Closed access
HXHong Xiao
Hong Xiao
TEThomas E. Edwards
Thomas E. Edwards
AFAdrian R. Ferré-D'AMaré
Adrian R. Ferré-D'AMaré